We studied the reciprocal effect of pregnancy and von Hippel-Lindau (VHL) disease by analyzing the influence of pregnancy on VHL disease-related lesions and VHL disease on pregnancy outcome.
tionnaire from 30 patients with VHL disease described a 5% self-reported VHL-related maternal morbidity. 7 Progression of VHL lesions during pregnancy could be explained by several factors. A rise in venous pressure by increased circulating blood volume and compression of the vena cava inferior to the growing uterus could be responsible for growth of hemangioblastomas. In addition, estrogeninduced endothelial proliferation is thought to stimulate stromal hemangioblastoma cell growth, and progesterone may increase venous distensibility. Placental-derived angiogenic factors might add to hemangioblastoma growth because proangiogenic factors are present in the maternal circulation. 8 We aimed to study the reciprocal effect of pregnancy and VHL disease by analyzing the influence of pregnancy on VHL disease-related lesions and of VHL disease on pregnancy outcome.
METHODS Subjects. We retrospectively studied 29 of 31 women with VHL disease who were receiving surveillance in VHL disease expertise centers in the Netherlands. The surveillance includes funduscopy, MRI of the spinal cord and cerebellum, CT scan or ultrasound of the abdomen, and determination of plasma and urine levels of metanephrines. 1 Diagnosis of VHL disease was based on clinical criteria or confirmed by germline mutation testing. Clinical criteria were met by either a positive family history of VHL disease with a personal history of at least one CNS hemangioblastoma, a case of RCC, or one pheochromocytoma or a personal history of 2 or more CNS hemangioblastomas or one CNS hemangioblastoma with a VHL disease-associated visceral lesion. 1, 9 Measurements. The influence of VHL disease on pregnancyrelated outcome and the influence of pregnancy on VHL disease activity were scored using the following parameters: 1) VHL disease-related complaints, number of VHL disease-related interventions, and size and number of individual VHL lesions; and 2) pregnancy-related fetal and maternal mortality and morbidity, VHL disease-associated and VHL disease-unrelated (e.g., pregnancy-related hypertensive disorders).
Data concerning VHL lesions leading to interventions or complaints before, during, and after pregnancy of all patients were extracted from medical records and completed by telephone interview or during outpatient clinic visits.
Data on all interventions performed within 4 years before and 4 years after pregnancy were collected. The severity of complaints before, during, and after pregnancy was subjectively scored as follows: 1 (no complaints), 2 (stable), 3 (progressive), and 4 (loss of function). Imaging reports (MRI scan, CT scan, ultrasound, or funduscopy), available for 15 pregnancies, were used to assess the effect of pregnancy on individual lesions in the cerebellum, spinal cord, retina, kidney, and pancreas. One or 2 measurements before and 1 or 2 measurements after pregnancy were collected with a maximum time span ranging from 4 years before the last menstruation until 4 years after delivery. Organ involvement was scored with a lesion progression score as follows: 1 (no lesions), 2 (stable), 3 (progression in number or size), or 4 (progression in number Ͼ2 or Ͼ2 cm in size, for retinal lesions threatened vision). The score 5 was noted when CNS and retinal lesions caused a life-threatening situation or blindness. Pheochromocytomas were scored as absent or present. In this design, patients served as their own control.
Standard protocol approvals, registrations, and patient consents. Patient identity was protected by unique patient
identifiers; codes were known only to 2 database managers. According to Dutch law no further institutional review board approval was required. All subjects provided written informed consent to participate in the study.
Statistical analysis. Statistical analysis was performed by the
Friedman test ( p Յ 0.05).
RESULTS
All 31 patients with VHL disease with at least one delivery known in the VHL disease centers were approached between April and September 2010. Two patients were excluded for personal and cognitive reasons, resulting in 29 patients and 48 pregnancies with 49 newborns (table 1). The women delivered between 1966 and 2010; 60% delivered after 1990. Renal cysts 3 (10)
Renal cell carcinoma 2 (7)
Pancreatic cysts 4 (14)
Pancreatic neuroendocrine tumor 0 (0) Abbreviation: VHL ϭ von Hippel-Lindau.
Maternal VHL disease-related complications occurred in 17% (n ϭ 8) of all pregnancies (table 2); in half of the women VHL disease was diagnosed before their pregnancy. In those 8 pregnancies, 10 VHL lesions led to new or increased complaints or intervention: hemangioblastoma cerebellum (n ϭ 2) and spinal cord (n ϭ 1), pheochromocytoma (n ϭ 2), RCC (n ϭ 1), and retinal angioma (n ϭ 4, 3 of which with major impaired vision loss/ablation). In 4 patients, a life-threatening situation emerged: cerebellar hemangioblastoma (n ϭ 2) and pheochromocytoma (n ϭ 2) (figure), resulting in 1 fetal death and 2 premature deliveries by cesarean section. All VHL disease complications occurred during a first pregnancy; 7 of these 8 patients did not pursue another pregnancy. Of the patients without a VHL disease complication, 67% had another pregnancy. The severity of VHL disease-related patient complaints during pregnancy (n ϭ 48) was significantly increased ( p ϭ 0.005). VHL disease interventions during pregnancy (n ϭ 7) and in the first year after delivery (n ϭ 8) were more frequent than those in the 4 years before pregnancy (average n ϭ 3).
Imaging-based progression scores of VHL disease-related lesions showed in the cerebellum a significant change of progression in the period between 1 MRI scan before and 2 MRI scans after pregnancy ( p ϭ 0.049). An increase in the progression score in the first measurement early after pregnancy has been measured at a mean of 6.4 months after delivery and can be considered as an effect of pregnancy. A decrease in progression score was found in the second MRI scan after pregnancy 1 year later (mean 18.7 months after delivery). In other organs, no significant progression of lesions was found. Maternal mortality rate was 0%; fetal death occurred in one patient (2%) at a gestational age of 32 weeks, caused by maternal hypertension from pheochromocytoma. Maternal pregnancy-related complications occurred in 15% of pregnancies (n ϭ 7); pregnancy-related hypertensive disorders were seen in 12.5% of patients (n ϭ 6), and one patient has intrahepatic cholestasis of pregnancy. DISCUSSION Increased activity of VHL disease, in particular of cerebellar hemangioblastomas, was observed in pregnancy. In 17% of patients, VHL disease-related complications were observed; VHL disease was diagnosed in only half of the patients before pregnancy. Four of 8 complicated pregnancies resulted in a life-threatening situation for mother and child (with one fetal death). Previously a VHL disease-related morbidity during pregnancy of 5.4% was found. 7 However, these data were derived from a written questionnaire sent to patients randomly. In our study, data were derived from medical reports, and all mothers with the diagnosis of VHL disease in the Dutch VHL disease expertise centers were evaluated.
Our result of cerebellar hemangioblastoma progression during pregnancy is in line with preliminary data showing a significantly higher complication rate for hemangioblastomas in patients with VHL disease with at least one pregnancy. 10 Possible explanations are the hormonal (growth factors and estrogen) and hemodynamic changes occurring during pregnancy, adding to the preexisting increased vascular endothelial growth factor expression (a direct downstream effect of biallelic VHL gene inactivation). 8 Therefore, a direct relationship between pregnancy and progression of cerebellar hemangioblastomas is likely. VHL disease-related lesions in other organs showed no significant change in progression score after pregnancy. This finding may be explained by the few patients with specific lesions and the age at onset of other VHL disease manifestations. In addition, the retrospective setting and the small sample size limit this study. However, larger series in this rare disease are difficult to achieve.
Our results show growth of VHL cerebellar hemangioblastomas during pregnancy and a high VHL disease complication rate during pregnancy. Intensi-fied surveillance of patients with VHL disease is recommended in a specialized medical center during preconception care and pregnancy. We recommend MRI of the cerebellum at 4 months of gestation and before delivery.
